Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Isaac T.W. Harley is active.

Publication


Featured researches published by Isaac T.W. Harley.


Nature Reviews Genetics | 2009

Genetic susceptibility to SLE: new insights from fine mapping and genome-wide association studies

Isaac T.W. Harley; Kenneth M. Kaufman; Carl D. Langefeld; John B. Harley; Jennifer A. Kelly

Genome-wide association studies and fine mapping of candidate regions have rapidly advanced our understanding of the genetic basis of systemic lupus erythematosus (SLE). More than 20 robust associations have now been identified and confirmed, providing insights at the molecular level that refine our understanding of the involvement of host immune response processes. In addition, genes with unknown roles in SLE pathophysiology have been identified. These findings may provide new routes towards improved clinical management of this complex disease.


Nature | 2009

Identification of IFRD1 as a modifier gene for cystic fibrosis lung disease

Yuanyuan Gu; Isaac T.W. Harley; Lindsay B. Henderson; Bruce J. Aronow; Ilja Vietor; Lukas A. Huber; John B. Harley; Jeffrey R. Kilpatrick; Carl D. Langefeld; Adrienne H. Williams; Anil G. Jegga; Jing Chen; Marsha Wills-Karp; S Hasan Arshad; Susan Ewart; Chloe L. Thio; Leah M. Flick; Marie Dominique Filippi; H. Leighton Grimes; Mitchell L. Drumm; Garry R. Cutting; Christopher L. Karp

Lung disease is the major cause of morbidity and mortality in cystic fibrosis, an autosomal recessive disease caused by mutations in CFTR. In cystic fibrosis, chronic infection and dysregulated neutrophilic inflammation lead to progressive airway destruction. The severity of cystic fibrosis lung disease has considerable heritability, independent of CFTR genotype. To identify genetic modifiers, here we performed a genome-wide single nucleotide polymorphism scan in one cohort of cystic fibrosis patients, replicating top candidates in an independent cohort. This approach identified IFRD1 as a modifier of cystic fibrosis lung disease severity. IFRD1 is a histone-deacetylase-dependent transcriptional co-regulator expressed during terminal neutrophil differentiation. Neutrophils, but not macrophages, from Ifrd1-deficient mice showed blunted effector function, associated with decreased NF-κB p65 transactivation. In vivo, IFRD1 deficiency caused delayed bacterial clearance from the airway, but also less inflammation and disease—a phenotype primarily dependent on haematopoietic cell expression, or lack of expression, of IFRD1. In humans, IFRD1 polymorphisms were significantly associated with variation in neutrophil effector function. These data indicate that IFRD1 modulates the pathogenesis of cystic fibrosis lung disease through the regulation of neutrophil effector function.Lung disease is the major cause of morbidity and mortality in cystic fibrosis (CF), an autosomal recessive disease caused by mutations in CFTR. In CF, chronic infection and dysregulated neutrophilic inflammation lead to progressive airway destruction. The severity of CF lung disease has significant heritability, independent of CFTR genotype1. To identify genetic modifiers, we performed a genome-wide single nucleotide polymorphism (SNP) scan in one cohort of CF patients, replicating top candidates in an independent cohort. This approach identified IFRD1 as a modifier of CF lung disease severity. IFRD1 is a histone deacetylase (HDAC)-dependent transcriptional co-regulator expressed during terminal neutrophil differentiation. Neutrophils, but not macrophages, from Ifrd1-deficient mice exhibited blunted effector function, associated with decreased NF-κB p65 transactivation. In vivo, IFRD1 deficiency caused delayed bacterial clearance from the airway, but also less inflammation and disease—a phenotype primarily dependent on hematopoietic cell expression, or lack of expression, of IFRD1. In humans, IFRD1 polymorphisms were significantly associated with variation in neutrophil effector function. These data suggest that IFRD1 modulates the pathogenesis of CF lung disease through regulation of neutrophil effector function.


Hepatology | 2014

IL-17 signaling accelerates the progression of nonalcoholic fatty liver disease in mice

Isaac T.W. Harley; Traci E. Stankiewicz; Daniel A. Giles; Samir Softic; Leah M. Flick; Monica Cappelletti; Rachel Sheridan; Stavra A. Xanthakos; Kris A. Steinbrecher; R. Balfour Sartor; Rohit Kohli; Christopher L. Karp; Senad Divanovic

Inflammation plays a central pathogenic role in the pernicious metabolic and end‐organ sequelae of obesity. Among these sequelae, nonalcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease in the developed world. The twinned observations that obesity is associated with increased activation of the interleukin (IL)‐17 axis and that this axis can regulate liver damage in diverse contexts prompted us to address the role of IL‐17RA signaling in the progression of NAFLD. We further examined whether microbe‐driven IL‐17A regulated NAFLD development and progression. We show here that IL‐17RA−/− mice respond to high‐fat diet stress with significantly greater weight gain, visceral adiposity, and hepatic steatosis than wild‐type controls. However, obesity‐driven lipid accumulation was uncoupled from its end‐organ consequences in IL‐17RA−/− mice, which exhibited decreased steatohepatitis, nicotinamide adenine dinucleotide phosphate (NADPH)‐oxidase enzyme expression, and hepatocellular damage. Neutralization of IL‐17A significantly reduced obesity‐driven hepatocellular damage in wild‐type mice. Further, colonization of mice with segmented filamentous bacteria (SFB), a commensal that induces IL‐17A production, exacerbated obesity‐induced hepatocellular damage. In contrast, SFB depletion protected from obesity‐induced hepatocellular damage. Conclusion: These data indicate that obesity‐driven activation of the IL‐17 axis is central to the development and progression of NAFLD to steatohepatitis and identify the IL‐17 pathway as a novel therapeutic target in this condition. (Hepatology 2014;59:1830–1839)


Mucosal Immunology | 2015

Distinct Tlr4-expressing cell compartments control neutrophilic and eosinophilic airway inflammation.

Jaclyn W. McAlees; G. S. Whitehead; Isaac T.W. Harley; Monica Cappelletti; Cheryl L. Rewerts; A. M. Holdcroft; Senad Divanovic; Marsha Wills-Karp; Fred D. Finkelman; Christopher L. Karp; D. N. Cook

Allergic asthma is a chronic, inflammatory lung disease. Some forms of allergic asthma are characterized by T helper type 2 (Th2)-driven eosinophilia, whereas others are distinguished by Th17-driven neutrophilia. Stimulation of Toll-like receptor 4 (TLR4) on hematopoietic and airway epithelial cells (AECs) contributes to the inflammatory response to lipopolysaccharide (LPS) and allergens, but the specific contribution of TLR4 in these cell compartments to airway inflammatory responses remains poorly understood. We used novel, conditionally mutant Tlr4fl/fl mice to define the relative contributions of AEC and hematopoietic cell Tlr4 expression to LPS- and allergen-induced airway inflammation. We found that Tlr4 expression by hematopoietic cells is critical for neutrophilic airway inflammation following LPS exposure and for Th17-driven neutrophilic responses to the house dust mite (HDM) lysates and ovalbumin (OVA). Conversely, Tlr4 expression by AECs was found to be important for robust eosinophilic airway inflammation following sensitization and challenge with these same allergens. Thus, Tlr4 expression by hematopoietic and airway epithelial cells controls distinct arms of the immune response to inhaled allergens.


American Journal of Human Genetics | 2014

Two Functional Lupus-Associated BLK Promoter Variants Control Cell-Type- and Developmental-Stage-Specific Transcription

Joel M. Guthridge; Rufei Lu; Harry Sun; Celi Sun; Graham B. Wiley; Nicolas Dominguez; Susan Macwana; Christopher J. Lessard; Xana Kim-Howard; Beth L. Cobb; Kenneth M. Kaufman; Jennifer A. Kelly; Carl D. Langefeld; Adam Adler; Isaac T.W. Harley; Joan T. Merrill; Gary S. Gilkeson; Diane L. Kamen; Timothy B. Niewold; Elizabeth E. Brown; Jeffery Edberg; Michelle Petri; Rosalind Ramsey-Goldman; John D. Reveille; Luis M. Vilá; Robert P. Kimberly; Barry I. Freedman; Anne M. Stevens; Susan A. Boackle; Lindsey A. Criswell

Efforts to identify lupus-associated causal variants in the FAM167A/BLK locus on 8p21 are hampered by highly associated noncausal variants. In this report, we used a trans-population mapping and sequencing strategy to identify a common variant (rs922483) in the proximal BLK promoter and a tri-allelic variant (rs1382568) in the upstream alternative BLK promoter as putative causal variants for association with systemic lupus erythematosus. The risk allele (T) at rs922483 reduced proximal promoter activity and modulated alternative promoter usage. Allelic differences at rs1382568 resulted in altered promoter activity in B progenitor cell lines. Thus, our results demonstrated that both lupus-associated functional variants contribute to the autoimmune disease association by modulating transcription of BLK in B cells and thus potentially altering immune responses.


Molecular metabolism | 2012

Obesity and the gut microbiome: Striving for causality

Isaac T.W. Harley; Christopher L. Karp

The gut microbiome has been proposed to play a causal role in obesity. Here, we review the historical context for this hypothesis, highlight recent key findings, and critically discuss issues central to further progress in the field, including the central epistemological problem for the field: how to define causality in the relationship between microbiota and obesity phenotypes. Definition of such will be critical for the field to move forward.


Arthritis & Rheumatism | 2012

Evaluation of TRAF6 in a large multiancestral lupus cohort

Bahram Namjou; Chan Bum Choi; Isaac T.W. Harley; Marta E. Alarcón-Riquelme; Jennifer A. Kelly; Stuart B. Glenn; Joshua O. Ojwang; Adam Adler; Kwangwoo Kim; Caroline J. Gallant; Susan A. Boackle; Lindsey A. Criswell; Robert P. Kimberly; Elizabeth E. Brown; Jeffrey C. Edberg; Graciela S. Alarcón; Anne M. Stevens; Chaim O. Jacob; Gary S. Gilkeson; Diane L. Kamen; Betty P. Tsao; Juan-Manuel Anaya; Eun Mi Kim; So Yeon Park; Yoon-Kyoung Sung; Joel M. Guthridge; Joan T. Merrill; Michelle Petri; Rosalind Ramsey-Goldman; Luis M. Vilá

OBJECTIVE Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with significant immune system aberrations resulting from complex heritable genetics as well as environmental factors. We undertook to study the role of TRAF6 as a candidate gene for SLE, since it plays a major role in several signaling pathways that are important for immunity and organ development. METHODS Fifteen single-nucleotide polymorphisms (SNPs) across TRAF6 were evaluated in 7,490 SLE patients and 6,780 control subjects from different ancestries. Population-based case-control association analyses and meta-analyses were performed. P values, false discovery rate q values, and odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated. RESULTS Evidence of associations was detected in multiple SNPs. The best overall P values were obtained for SNPs rs5030437 and rs4755453 (P = 7.85 × 10(-5) and P = 4.73 × 10(-5) , respectively) without significant heterogeneity among populations (P = 0.67 and P = 0.50, respectively, in Q statistic). In addition, SNP rs540386, which was previously reported to be associated with rheumatoid arthritis (RA), was found to be in linkage disequilibrium with these 2 SNPs (r(2) = 0.95) and demonstrated evidence of association with SLE in the same direction (meta-analysis P = 9.15 × 10(-4) , OR 0.89 [95% CI 0.83-0.95]). The presence of thrombocytopenia improved the overall results in different populations (meta-analysis P = 1.99 × 10(-6) , OR 0.57 [95% CI 0.45-0.72], for rs5030470). Finally, evidence of family-based association in 34 African American pedigrees with the presence of thrombocytopenia was detected in 1 available SNP (rs5030437) with a Z score magnitude of 2.28 (P = 0.02) under a dominant model. CONCLUSION Our data indicate the presence of association of TRAF6 with SLE, consistent with the previous report of association with RA. These data provide further support for the involvement of TRAF6 in the pathogenesis of autoimmunity.


BioMed Research International | 2010

The Role of Genetic Variation Near Interferon-Kappa in Systemic Lupus Erythematosus

Isaac T.W. Harley; Timothy B. Niewold; Rebecca M. Stormont; Kenneth M. Kaufman; Stuart B. Glenn; Beverly S. Franek; Jennifer A. Kelly; J. Kilpatrick; David Hutchings; Jasmin Divers; Gail R. Bruner; Jeffrey C. Edberg; Gerald McGwin; Michelle Petri; Rosalind Ramsey-Goldman; John D. Reveille; Luis M. Vilá-Pérez; Joan T. Merrill; Gary S. Gilkeson; Timothy J. Vyse; Marta E. Alarcón-Riquelme; Soo-Kyung Cho; Chaim O. Jacob; Graciela S. Alarcón; Kathy L. Moser; Patrick M. Gaffney; Robert P. Kimberly; Sang-Cheol Bae; Carl D. Langefeld; John B. Harley

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by increased type I interferons (IFNs) and multiorgan inflammation frequently targeting the skin. IFN-kappa is a type I IFN expressed in skin. A pooled genome-wide scan implicated the IFNK locus in SLE susceptibility. We studied IFNK single nucleotide polymorphisms (SNPs) in 3982 SLE cases and 4275 controls, composed of European (EA), African-American (AA), and Asian ancestry. rs12553951C was associated with SLE in EA males (odds ratio = 1.93, P = 2.5 × 10−4), but not females. Suggestive associations with skin phenotypes in EA and AA females were found, and these were also sex-specific. IFNK SNPs were associated with increased serum type I IFN in EA and AA SLE patients. Our data suggest a sex-dependent association between IFNK SNPs and SLE and skin phenotypes. The serum IFN association suggests that IFNK variants could influence type I IFN producing plasmacytoid dendritic cells in affected skin.


Molecular metabolism | 2013

Differential colonization with segmented filamentous bacteria and Lactobacillus murinus do not drive divergent development of diet-induced obesity in C57BL/6 mice.

Isaac T.W. Harley; Daniel A. Giles; Paul T. Pfluger; Stacey L. Burgess; Stephanie Walters; Jazzminn Hembree; Christine Raver; Cheryl L. Rewerts; Jordan Downey; Leah M. Flick; Traci E. Stankiewicz; Jaclyn W. McAlees; Marsha Wills-Karp; R. Balfour Sartor; Senad Divanovic; Matthias H. Tschöp; Christopher L. Karp

Alterations in the gut microbiota have been proposed to modify the development and maintenance of obesity and its sequelae. Definition of underlying mechanisms has lagged, although the ability of commensal gut microbes to drive pathways involved in inflammation and metabolism has generated compelling, testable hypotheses. We studied C57BL/6 mice from two vendors that differ in their obesogenic response and in their colonization by specific members of the gut microbiota having well-described roles in regulating gut immune responses. We confirmed the presence of robust differences in weight gain in mice from these different vendors during high fat diet stress. However, neither specific, highly divergent members of the gut microbiota (Lactobacillus murinus, segmented filamentous bacteria) nor the horizontally transmissible gut microbiota were found to be responsible. Constitutive differences in locomotor activity were observed, however. These data underscore the importance of selecting appropriate controls in this widely used model of human obesity.


Pediatric Blood & Cancer | 2010

MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: A report from the Children's Oncology Group†

Christine L. Phillips; Robert B. Gerbing; Todd A. Alonzo; John P. Perentesis; Isaac T.W. Harley; Soheil Meshinchi; Deepika Bhatla; Gretchen A. Radloff; Stella M. Davies

The variant polymorphism in the gene MDM2, SNP309, leads to increased level of mdm2 protein and subsequent downregulation of p53 tumor suppressor pathway. Presence of this single nucleotide polymorphism (SNP) has been associated with earlier tumorigenesis in patients with Li–Fraumeni syndrome, as well as decreased survival in patients with CLL. In addition, cells homozygous (G/G) for SNP 309 were found to have 10‐fold increase resistance to topoisomerase II inhibitors in vitro.

Collaboration


Dive into the Isaac T.W. Harley's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Gary S. Gilkeson

Medical University of South Carolina

View shared research outputs
Top Co-Authors

Avatar

Jennifer A. Kelly

Oklahoma Medical Research Foundation

View shared research outputs
Top Co-Authors

Avatar

Michelle Petri

Johns Hopkins University School of Medicine

View shared research outputs
Top Co-Authors

Avatar

Senad Divanovic

Cincinnati Children's Hospital Medical Center

View shared research outputs
Top Co-Authors

Avatar

Elizabeth E. Brown

University of Alabama at Birmingham

View shared research outputs
Top Co-Authors

Avatar

Graciela S. Alarcón

University of Alabama at Birmingham

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

John D. Reveille

University of Texas at Austin

View shared research outputs
Researchain Logo
Decentralizing Knowledge